Overview

Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy

Status:
Active, not recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, controlled, open-label phase II study including patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine and Platinum-based drugs.

Phase:

Phase 2

Details

Lead Sponsor:

IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators:

Eli Lilly and Company
Trium Analysis Online GmbH

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Paclitaxel
Ramucirumab